Ginkgo Bioworks Holdings, Inc. DNA
10.15 USD -0.11 (-1.02%)
Nov 12, 2026, 11:50 AM EST
9.56 Day range 10.14
5.37 52-week range 18.22
- YTD
- +22.08%
- 1 year
- +21.35%
News
globenewswire.com Rakovina Therapeutics Secures Exclusive Worldwide Licence to Artemis.AI™ Platform for DNA-Damage Response Oncology Drug Discovery Perpetual, royalty-free, exclusive licence for DDR oncology including all future platform improvements, in exchange for C$1.0 million in Rakovina shares Perpetual, royalty-free, exclusive licence for…
fool.com Ginkgo Bioworks: 3 Key Takeaways for Long-Term Investors Novo Nordisk selected Ginkgo to build an autonomous research laboratory. Ginkgo ended the third quarter with $285 million in cash.
marketbeat.com Ginkgo Bioworks Q3 Earnings Call Highlights Ginkgo Bioworks NYSE: DNA reported lower third-quarter revenue but narrowed its loss as restructuring-related expense cuts took hold, while executives highlighted new customers for its autonomous…
seekingalpha.com Ginkgo Bioworks Holdings, Inc. (DNA) Q3 2026 Earnings Call Transcript Ginkgo Bioworks Holdings, Inc. (DNA) Q3 2026 Earnings Call Transcript
businesswire.com Ginkgo Bioworks Reports Third Quarter 2026 Results; Signs First Autonomous Lab Sale to a Top-Tier Pharma Company Novo BOSTON--(BUSINESS WIRE)--Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, “Ginkgo”) today announced its results for the third quarter of 2026 that ended September 30, 2026. The update, including a webcast…
benzinga.com TD Cowen Maintains Hold on Ginkgo Bioworks Holdings, Raises Price Target to $11 TD Cowen analyst Brendan Smith maintains Ginkgo Bioworks Holdings (NYSE:DNA) with a Hold and raises the price target from $9 to $11.
benzinga.com Glaukos Reveals Superior Intraocular Pressure Reduction With Novel Eye Therapy Glaukos reports positive Phase 4 results for its iDose TR therapy, demonstrating superior efficacy over standalone cataract surgery.
benzinga.com What's Going on With Ginkgo Bioworks Stock on Friday? Ginkgo Bioworks offers remote autonomous lab access to NSF X-Labs and integrates Araceli imaging into its Boston platform.
benzinga.com Humana, Evolution Metals & Technologies, Fastly And Other Big Stocks Moving Higher On Friday U.S. stocks rose Friday; Humana jumped 12.3% after improved 2027 Medicare Advantage ratings and reaffirmed FY26 EPS guidance.
benzinga.com Ginkgo Bioworks To Provide Autonomous Lab Access To NSF X-Labs Researchers, Contributing Cloud Lab Time And Protein Testing Services To $1.5B Science Program; To Provide Cloud Lab Time And Remote Access For NSF X-Labs Teams; To Offer Protein Testing Services To NSF X-Labs Teams Ginkgo Bioworks (NYSE:DNA) today announced that it will provide in-kind access to its autonomous laboratory in Boston to support the National Science Foundation’s X-Labs program. Ginkgo’s support was…
benzinga.com Ginkgo Bioworks To Integrate Araceli Biosciences' Endeavor High-Content Imaging Instrument Into Nebula, The Company's Autonomous Lab The Endeavor, the world's fastest high-content imaging system, brings cellular imaging with real-time analysis to Nebula's existing technologies, giving researchers the large, curated datasets needed…
benzinga.com Apogee Enterprises Posts Upbeat Q2 Earnings, Joins Constellation Energy, Freshworks And Other Big Stocks Moving Higher On Tuesday U.S. stocks rose; Apogee surged 10% on strong results and raised guidance, while Option Care, Ginkgo, PacBio and others posted double-digit gains.
benzinga.com Everpure, Fervo Energy, Charles River Laboratories And Other Big Stocks Moving Higher On Thursday Nasdaq fell 150+ points, while Everpure jumped 14% after unveiling growth plans and a FY2028 outlook; other stocks also gained.
benzinga.com BTIG Reiterates Sell on Ginkgo Bioworks Holdings, Maintains $5 Price Target BTIG analyst Mark Massaro reiterates Ginkgo Bioworks Holdings (NYSE:DNA) with a Sell and maintains $5 price target.
benzinga.com Estee Lauder, Moderna, Merck And Other Big Stocks Moving Higher On Wednesday Dow Jones up 200 points on Wed. Estee Lauder & other top stocks record gains after reporting strong Q4 results and positive sales guidance.- benzinga.com TD Cowen Downgrades Ginkgo Bioworks Holdings to Hold, Lowers Price Target to $9 TD Cowen analyst Brendan Smith downgrades Ginkgo Bioworks Holdings (NYSE:DNA) from Buy to Hold and lowers the price target from $12 to $9.
- benzinga.com U.S. CDC Says Will Enhance Screening And Monitoring Of Travelers Arriving From Areas Affected By Ebola Outbreaks; Will Coordinate With Airlines, Others To Manage Travelers Who May Have Already Been Exposed To Ebola; Will Enhance Contract Tracing, Hospital Readiness Nationwide https://www.cdc.gov/ebola/situation-summary/index.html
- benzinga.com ProQR Therapeutics Collaborates With Ginkgo Bioworks Over Access To 50+ Instrument Autonomous Lab Nebula ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today…
- benzinga.com BTIG Maintains Sell on Ginkgo Bioworks Holdings, Lowers Price Target to $5 BTIG analyst Mark Massaro maintains Ginkgo Bioworks Holdings (NYSE:DNA) with a Sell and lowers the price target from $9 to $5.
benzinga.com Elon Musk Endorses 'Fundable' Jurassic Park: These De-Extinction Companies Are Already Making It Happen Elon Musk tweeted about wanting Jurassic Park in real life. Companies aren't bringing back dinosaurs yet, but they are bringing extinct items back to life.
benzinga.com Ginkgo Bioworks Rolls Out Ginkgo Cloud Lab Ginkgo Bioworks (NYSE: DNA) today announced the official launch of Ginkgo Cloud Lab. This new interface allows researchers to transition their benchwork to Ginkgo's autonomous lab infrastructure…
benzinga.com Flutter Entertainment Posts Downbeat Q4 Results, Joins Zscaler, Elastic And Other Big Stocks Moving Lower In Friday's Pre-Market Session (CORRECTED) 
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session 
benzinga.com Ginkgo Bioworks Pivots To AI And Robotics After Rough Quarter Ginkgo Bioworks stock drops after earnings miss, lower sales, and shift to autonomous labs and robotics focus.
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session 
benzinga.com Why Applied Optoelectronics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket 
benzinga.com Ginkgo Bioworks To Spin Off Biosecurity Business To Investor Consortium In Exchange For A Minority Equity Position In The Business Alongside The Investors Ginkgo today announced it has reached an agreement to sell the Company's biosecurity business to a consortium of investors ("Investors") in exchange for a minority equity position in the business…
benzinga.com Ginkgo Bioworks Holdings Q4 EPS $(1.41) Misses $(1.36) Estimate, Sales $33.318M Miss $37.617M Estimate Ginkgo Bioworks Holdings (NYSE:DNA) reported quarterly losses of $(1.41) per share which missed the analyst consensus estimate of $(1.36) by 3.68 percent. This is a 29.5 percent increase over losses…
benzinga.com Earnings Scheduled For February 26, 2026 
benzinga.com Insights into Ginkgo Bioworks Holdings's Upcoming Earnings - benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com Why Roblox Shares Are Trading Higher By Over 14%; Here Are 20 Stocks Moving Premarket 
benzinga.com Ginkgo Bioworks Demonstrates, In Collaboration With OpenAI, An AI System That Autonomously Designed, Executed, And Learned From Biological Experiments With Minimal Human Involvement; Co. Reports The System Reduced Cell-Free Protein Synthesis Reaction Costs By 40% Relative To State Of The Art; GPT-5-Driven Autonomous Lab Executed Over 36,000 Experiments Ginkgo Bioworks (NYSE:DNA) today announced it has demonstrated, in collaboration with OpenAI, an AI system that autonomously designed, executed, and learned from biological experiments with minimal…- benzinga.com TD Cowen Maintains Buy on Ginkgo Bioworks Holdings, Lowers Price Target to $12 TD Cowen analyst Brendan Smith maintains Ginkgo Bioworks Holdings (NYSE:DNA) with a Buy and lowers the price target from $14 to $12.
benzinga.com Ginkgo Bioworks (DNA) Shares Rise On New Cancer Screening Approach Plans Ginkgo Bioworks shares are trading higher Monday afternoon, up over 8%, following the announcement of a strategic partnership with Carnegie Mellon University.- benzinga.com ProteoNic's 2G UNic Technology Licensed By Ginkgo Bioworks For Use In $22.2M Project Awarded To Ginkgo By Biomedical Advanced Research And Development Authority ProteoNic BV, a leading provider of premium vector technology for biopharmaceutical and viral vector production, today announced that its proprietary 2G UNic® technology has been licensed by Ginkgo…
- benzinga.com Ginkgo Bioworks Awarded 4-Yr, Up To $47M Contract By EMSL To Co-Design, Build, And Integrate High‑Throughput Automated Phenotyping Platform In Support Of M2PC Ginkgo Bioworks (NYSE:DNA) today announced it has been awarded by the Environmental Molecular Sciences Laboratory (EMSL) at Pacific Northwest National Laboratory (PNNL) a four-year, up to $47M…
benzinga.com Ginkgo Bioworks Stock Plummets Following Q3 Estimates Miss, Reaffirms FY2025 Outlook Below Consensus Ginkgo Bioworks Holdings Inc (NYSE:DNA) shares are trading lower on Friday. The company released its third-quarter financial results.- benzinga.com Ginkgo Bioworks Holdings Affirms FY2025 Sales Guidance of $167.000M-$187.000M vs $177.075M Est Ginkgo Bioworks Holdings (NYSE:DNA) affirms FY2025 sales outlook from $167.000 million-$187.000 million to $167.000 million-$187.000 million vs $177.075 million estimate.
- benzinga.com Ginkgo Bioworks Holdings Q3 EPS $(1.45) Misses $(1.24) Estimate, Sales $38.837M Miss $38.850M Estimate Ginkgo Bioworks Holdings (NYSE:DNA) reported quarterly losses of $(1.45) per share which missed the analyst consensus estimate of $(1.24) by 16.94 percent. This is a 34.26 percent decrease over…
benzinga.com Earnings Scheduled For November 6, 2025 - benzinga.com Ginkgo Bioworks Awarded Up To $22.2M Contract From Biopharmaceutical Manufacturing Preparedness Consortium To Develop Innovations To Lower Costs Of Local Biomanufacturing Of Monoclonal Antibodies Ginkgo Bioworks (NYSE: DNA) announced today that it has been awarded a contract through the Biomedical Advanced Research and Development Authority's (BARDA) Biopharmaceutical Manufacturing…
- benzinga.com Ginkgo Bioworks Extends Its Multi-Year Partnership With Bayer To Continue Developing Biological Products For Agriculture, Focusing On Microbial Nitrogen Fixation Ginkgo Bioworks (NYSE:DNA) today announced that the company has extended its multi-year strategic partnership with Bayer to advance research and development of biological products for agriculture.…
benzinga.com Ginkgo Bioworks Collaborates With STRM.BIO And University Of British Columbia To Develop In Vivo Chimeric Antigen Receptor Therapies For Autoimmune Diseases Ginkgo Bioworks to apply its RNA construct design expertise to develop long-lived, tissue-specific, and highly potent in vivo CAR therapies for autoimmune diseasesBOSTON, Oct. 23, 2025 /PRNewswire/…
benzinga.com Dell, Select Medical, Century Aluminum And Other Big Stocks Moving Higher On Wednesday - benzinga.com BTIG Maintains Sell on Ginkgo Bioworks Holdings, Raises Price Target to $9 BTIG analyst Mark Massaro maintains Ginkgo Bioworks Holdings (NYSE:DNA) with a Sell and raises the price target from $6 to $9.
benzinga.com 5 Healthcare Stocks On Fire This Week Healthcare stocks SNOA, EVOK, KALA, DNA, & SNGX soar with massive momentum gains, signaling breakout potential in biotech & pharma.- benzinga.com Ginkgo Bioworks Announces Strategic Partnership To Scale AI Drug Discovery Via Datapoints Platform Ginkgo Bioworks (NYSE:DNA), which is building the leading platform for cell programming and biosecurity, today announced that its Datapoints offering has entered into a new strategic partnership with…
- benzinga.com Ginkgo Bioworks Holdings Q2 EPS $(1.10) Beats $(1.56) Estimate, Sales $50.00M Beat $41.61M Estimate Ginkgo Bioworks Holdings (NYSE:DNA) reported quarterly losses of $(1.10) per share which beat the analyst consensus estimate of $(1.56) by 29.49 percent. This is a 75 percent increase over losses of…
- benzinga.com Ginkgo Bioworks Holdings Affirms FY2025 Sales Guidance of $167.000M-$187.000M vs $178.213M Est Ginkgo Bioworks Holdings (NYSE:DNA) affirms FY2025 sales outlook from $167.000 million-$187.000 million to $167.000 million-$187.000 million vs $178.213 million estimate.